In TNBC, EZH2 can epigenetically modify TET1 through H3K27me3, thereby inhibiting the expression of the tumor suppressor gene TET1 (an activator of p53 tumor suppressor signaling pathway). The gene discussed is TET1; the disease is neoplasm.